Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group
- PMID: 1694945
Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group
Erratum in
- Lancet 1990 Sep 15;336(8716):698
Abstract
516 patients with New York Heart Association class III and IV heart failure despite treatment with diuretics and angiotensin converting enzyme inhibitors were randomised in a double-blind between-group comparison to xamoterol 200 mg (352) or placebo (164) twice daily for 13 weeks. There was no difference between the treatments in loss of clinical signs. Visual analogue scale and Likert scores indicated that breathlessness was less severe with xamoterol, but there was no difference in exercise duration or total work done. Xamoterol reduced maximum exercise heart rate and systolic blood pressure, did not affect the number of ventricular premature beats after exercise, showed no arrhythmogenic activity, and had variable (agonist and antagonist) effects on 24 h heart rate. On intention-to-treat analysis 32 (9.1%) patients in the xamoterol group and 6 (3.7%) patients in the placebo group died within 100 days of randomisation (p = 0.02).
Comment in
-
New evidence on xamoterol.Lancet. 1990 Jul 7;336(8706):24. Lancet. 1990. PMID: 1973213 No abstract available.
-
Xamoterol in severe heart failure.Lancet. 1990 Aug 25;336(8713):517-8. doi: 10.1016/0140-6736(90)92078-v. Lancet. 1990. PMID: 1975033 No abstract available.
Similar articles
-
Lack of tolerance development after long-term administration of the partial beta-adrenoceptor agonist xamoterol.Cardiology. 1990;77(1):30-9. doi: 10.1159/000174577. Cardiology. 1990. PMID: 1972349 Clinical Trial.
-
Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. The German and Austrian Xamoterol Study Group.Lancet. 1988 Mar 5;1(8584):489-93. Lancet. 1988. PMID: 2893916 Clinical Trial.
-
Effects of xamoterol in acute myocardial infarction: blood pressure, heart rate, arrhythmias and early clinical course.Int J Cardiol. 1991 Jun;31(3):295-303. doi: 10.1016/0167-5273(91)90380-8. Int J Cardiol. 1991. PMID: 1679047 Clinical Trial.
-
Review of clinical experience with xamoterol. Effects on exercise capacity and symptoms in heart failure.Circulation. 1990 Feb;81(2 Suppl):III93-8. Circulation. 1990. PMID: 1967561 Review.
-
Xamoterol, a beta 1-adrenoceptor partial agonist: review of the clinical efficacy in heart failure.Br J Clin Pharmacol. 1989;28 Suppl 1(Suppl 1):23S-30S. doi: 10.1111/j.1365-2125.1989.tb03570.x. Br J Clin Pharmacol. 1989. PMID: 2572251 Free PMC article. Review.
Cited by
-
Surely a natural cancer remedy can't be dangerous.BMJ. 1990 Dec 1;301(6763):1280. doi: 10.1136/bmj.301.6763.1280-a. BMJ. 1990. PMID: 2271845 Free PMC article. No abstract available.
-
Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling.Trends Pharmacol Sci. 2011 Apr;32(4):227-34. doi: 10.1016/j.tips.2011.02.010. Epub 2011 Mar 21. Trends Pharmacol Sci. 2011. PMID: 21429598 Free PMC article. Review.
-
Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists.J Med Chem. 2013 May 23;56(10):3852-65. doi: 10.1021/jm400348g. Epub 2013 May 10. J Med Chem. 2013. PMID: 23614528 Free PMC article.
-
Understanding cardiac output.Crit Care. 2008;12(4):174. doi: 10.1186/cc6975. Epub 2008 Aug 22. Crit Care. 2008. PMID: 18771592 Free PMC article.
-
Heart failure treatments: issues of safety versus issues of quality of life.Drug Saf. 1999 Jan;20(1):1-7. doi: 10.2165/00002018-199920010-00001. Drug Saf. 1999. PMID: 9935272 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
